Biopharmaceutical researcher Omeros (OMER +1.6%) moves up after being upgraded to Buy at...

|About: Omeros Corporation (OMER)|By:, SA News Editor

Biopharmaceutical researcher Omeros (OMER +1.6%) moves up after being upgraded to Buy at Canaccord earlier this morning, citing impressive efficacy data from its OMS302 Phase 3 trial. The firm also raises its price target to $13 from $5.